Thomas Niel is a Contributor at NXTmine. He focuses on finance, trading, and personal finance, with expertise in credit health, debt management, retirement planning, and global markets. His insights have been featured in NXTmine, Yahoo Finance, InvestorPlace, Seeking Alpha, The Motley Fool, and MSN.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Thomas Niel's articles primarily focus on investment analysis and stock market trends, particularly within the finance and sales & marketing sectors. He seems to have an interest in providing insights into specific stocks and their potential for growth or decline.
If you're looking to reach out to Thomas, consider offering expert analysis or data-driven insights related to investment opportunities, stock performance, or emerging market trends within the finance industry. Additionally, if you have expertise in evaluating dividend stocks or tech companies' financial performances, your input could be valuable for his coverage.
This information evolves through artificial intelligence and human feedback. Improve this profile .
It may be too late for Viking to take on the "dark horse" role in the GLP-1 wars.
The bull case still hinges on legalization's progress. Tilray Brands TLRY is far from perfect, but the Canada-based cannabis company's fundamentals have improved recently.
By: Thomas Niel
Berkshire cashed out of UnitedHealth before the recent rally, but that doesn't mean Abel sold too early.
This eVTOL pioneer is gaining an early-mover advantage in what could scale into a trillion-dollar industry.
By: Thomas Niel
Teva's transformation is gaining momentum. Consider Teva Pharmaceutical Industries TEVA the "comeback kid" among pharmaceutical stocks.
By: Thomas Niel
Growth, not yield, is the deciding factor. CVS Health CVS and UnitedHealth Group UNH are two of the most widely followed healthcare
In which of these cannabis stocks should investors plant their money?
By: Thomas Niel
Tread carefully, but certain factors make this speculative biotech play stand out. Iovance Biotherapeutics IOVA is not for the faint of heart.
By: Thomas Niel
The Microsoft founder's foundation recently added this healthcare stock to its portfolio.
By: Thomas Niel
Durability, not yield, is the deciding factor. When it comes to pharmaceutical stocks and yield, Bristol Myers Squibb BMY and Pfizer PFE stand out.
